Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women

M. Meschia, M. Brincat, P. Barbacini, M. Carena Maini, R. Marri, P. G. Crosignani

Research output: Contribution to journalArticlepeer-review

Abstract

A total of 104 postmenopausal women were randomly assigned to different therapeutic regimens: (a) calcitonin, (b) estrogen/progestogen (HRT) plus calcitonin, (c) estrogen/progestogen (HRT), (d) and the control group. The bone mass of the lumbar vertebrae of all patients was assessed with a dual beam photon absorptiometer (Norland GD 153). The 73 patients who completed the 1-yr study showed that postmenopausal bone loss could be prevented by either estrogen/progestogen (HRT) or calcitonin. In addition, the combination of hormonel replacement therapy and calcitonin not only prevented postmenopausal bone loss but resulted in a significant 10% gain in bone mass (P <0.001).

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
Volume47
Issue number1
DOIs
Publication statusPublished - Oct 23 1992

Keywords

  • Bone loss
  • Calcitonin
  • HRT

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Fingerprint Dive into the research topics of 'Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women'. Together they form a unique fingerprint.

Cite this